Mobile site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

Request A Rep

Please complete this form, and a Takeda representative will contact you.

All fields are required.

Preferred contact method

By clicking the box above and providing your information, you consent to receiving marketing and promotional communications related to hereditary angioedema (HAE) and HAE products and other information from Takeda. You hereby give consent to Takeda, its affiliates, and their agents and representatives to send communications and information to you via the contact information you have provided above. This consent will be in effect until such time as you opt out of communications from Takeda. If, at any time, you no longer wish to receive communications from Takeda, you can opt out by calling 1-877-TAKEDA-7 (1-877-825-3327). Please see our privacy policy.